Grufity logo
Grufity logo

Latest ARCH VENTURE CORP Stock Portfolio

$677Million– No. of Holdings #10

ARCH VENTURE CORP Performance:
2026 Q1: 5.51%YTD: 5.51%2025: 73.87%
Performance for 2026 Q1 is 5.51%, and YTD is 5.51%, and 2025 is 73.87%.

About ARCH VENTURE CORP and 13F Hedge Fund Stock Holdings

On 2026-05-15, the fund reported it's updated stock portfolio. In the 13F Holdings report, ARCH Venture Management, LLC reported an equity portfolio of $677.1 Millions as of 31 Mar, 2026.

The top stock holdings of ARCH Venture Management, LLC are , , VIR. The fund has invested 18.2% of it's portfolio in MAZE THERAPEUTICS INC and 17.2% of portfolio in RAPPORT THERAPEUTICS INC.

They significantly reduced their stock positions in 10X GENOMICS INC (TXG) and ERASCA INC (ERAS). ARCH Venture Management, LLC opened new stock positions in GENERATE BIOMEDICINES INC. The fund showed a lot of confidence in some stocks as they added substantially to LYELL IMMUNOPHARMA INC (LYEL).
ARCH VENTURE CORP Equity Portfolio Value
Last Reported on: 15 May, 2026

ARCH VENTURE CORP Annual Return Estimates Vs S&P 500

Our best estimate is that ARCH Venture Management, LLC made a return of 5.51% in the last quarter. In trailing 12 months, it's portfolio return was 142.46%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
generate biomedicines inc24,305,300
New stocks bought by ARCH VENTURE CORP

Additions

Ticker% Inc.
lyell immunopharma inc17.69
Additions to existing portfolio by ARCH VENTURE CORP

Reductions

Ticker% Reduced
10x genomics inc-70.46
erasca inc-35.86
ARCH VENTURE CORP reduced stake in above stock

Sold off

None of the stocks were completely sold off by ARCH VENTURE CORP

Sector Distribution

ARCH Venture Management, LLC has about 60.7% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
Sector%
Healthcare60.7
Others39.3

Market Cap. Distribution

ARCH Venture Management, LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.

  • UNALLOCATED
  • MID-CAP
  • SMALL-CAP
Category%
UNALLOCATED39.3
MID-CAP33.6
SMALL-CAP27.1

Stocks belong to which Index?

About 59.6% of the stocks held by ARCH Venture Management, LLC either belong to S&P 500 or RUSSELL 2000 index.

  • RUSSELL 2000
  • Others
Index%
RUSSELL 200059.6
Others40.4
Top 5 Winners (%)%
ERAS
erasca inc
274.9 %
q32 bio inc
93.4 %
VIR
vir biotechnology inc
48.6 %
TXG
10x genomics inc
19.5 %
rapport therapeutics inc
3.1 %
Top 5 Winners ($)$
ERAS
erasca inc
113.1 M
VIR
vir biotechnology inc
37.8 M
rapport therapeutics inc
3.5 M
TXG
10x genomics inc
2.4 M
q32 bio inc
1.0 M
Top 5 Losers (%)%
GOSS
gossamer bio inc
-89.4 %
LYEL
lyell immunopharma inc
-33.1 %
maze therapeutics inc
-27.9 %
BEAM
beam therapeutics inc
-14.0 %
Top 5 Losers ($)$
maze therapeutics inc
-47.7 M
LYEL
lyell immunopharma inc
-32.2 M
GOSS
gossamer bio inc
-22.3 M
BEAM
beam therapeutics inc
-17.7 M

ARCH VENTURE CORP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of ARCH VENTURE CORP

ARCH Venture Management, LLC has 10 stocks in it's portfolio. proved to be the most loss making stock for the portfolio. ERAS was the most profitable stock for ARCH Venture Management, LLC last quarter.

Last Reported on: 15 May, 2026
TickerNamesorted ascending% PortfolioShares Held$ ValueType% ChangeOptions